Monuril (Fosfomycin)

Fosfomycin blocks the bacterial enzyme MurA, preventing the formation of N‑acetylmuramic acid, an essential building block of the peptidoglycan cell wall. Without a functional cell wall, bacteria cannot survive, leading to their death and clearance of the infection.

The prescribed dose of Monuril is determined by the treating clinician based on the patient’s condition and local guidelines. Typically, a single 3 g sachet is reconstituted for oral administration, but the exact regimen should follow the prescriber’s instructions.

The safety of fosfomycin in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Monuril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monuril offers a single‑dose oral regimen, which differs from multi‑day courses of trimethoprim‑sulfamethoxazole or fluoroquinolones. Its unique mechanism targeting cell‑wall synthesis can be effective against resistant strains, but susceptibility testing is recommended to ensure optimal therapy.

Monuril should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. The powder for suspension remains stable at room temperature, but reconstituted suspension should be used promptly and discarded after the recommended period.

Monuril is supplied as a 3 g oral powder that is mixed with a measured amount of water to create a suspension. The patient drinks the prepared suspension once, following the instructions provided by the healthcare professional.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they develop rash, fever, persistent diarrhea, or signs of hypersensitivity.

Monuril should be avoided in individuals with a known hypersensitivity to fosfomycin or any component of the formulation. Caution is also advised for patients with severe renal impairment, pregnant or breastfeeding women unless clearly indicated, and those taking interacting medications without proper monitoring.